<DOC>
	<DOCNO>NCT00415116</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth solid tumor block blood flow tumor . Drugs use chemotherapy , docetaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving lenalidomide together docetaxel carboplatin may kill tumor cell . PURPOSE : This phase I trial study side effect best dose lenalidomide give together docetaxel carboplatin treat patient advance solid tumor .</brief_summary>
	<brief_title>Lenalidomide , Docetaxel , Carboplatin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose lenalidomide administer docetaxel carboplatin patient advance solid tumor . Secondary - Determine safety toxic effect regimen patient . - Determine , preliminarily , clinical activity regimen patient . OUTLINE : This open-label , dose-escalation study lenalidomide . Patients receive docetaxel IV 1 hour follow carboplatin IV day 1 . Patients also receive oral lenalidomide daily day 1-14 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients stable respond disease completion 6 course treatment may continue lenalidomide alone daily day 1-14 . Patients whose disease stable respond complete 2 4 course unable tolerate chemotherapy may continue lenalidomide alone daily day 1-14 , investigator 's discretion . Treatment lenalidomide repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos lenalidomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional 6-8 patient treat MTD . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven solid tumor Measurable evaluable disease Refractory standard treatment No prior failure docetaxel carboplatin regimen except adjuvant set History brain disease allow , provide follow criterion meet : Brain disease previously treat radiotherapy surgery Asymptomatic active brain disease , document CT scan MRI , least 3 month PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 mg/dL Bilirubin normal AST ALT ≤ 2 time upper limit normal ( ULN ) ( 5 time ULN hepatic metastasis present ) Alkaline phosphatase ≤ 3 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week completion study treatment No serious medical condition , laboratory abnormality , psychiatric illness would preclude give informed consent , expose patient unacceptable risk , affect interpretation study data No known hypersensitivity thalidomide No history erythema nodosum , characterize desquamate rash , take thalidomide similar drug No preexist peripheral neuropathy ≥ grade 2 No know hypersensitivity intolerance taxanes No known HIV positivity No known infectious hepatitis , type A , B , C PRIOR CONCURRENT THERAPY : See Disease Characteristics No 2 prior chemotherapy regimen At least 28 day since prior cancer therapy , include radiotherapy , biologic therapy , hormonal therapy , chemotherapy , surgery At least 28 day since prior investigational drug therapy No prior lenalidomide No concurrent chemotherapy biologic therapy No concurrent radiotherapy No concurrent use anticancer agent treatments No prophylactic granulocyte colonystimulating factor ( GCSF ) first course study treatment No concurrent prophylactic antibiotic No concurrent treatment follow medication : Systemic corticosteroid ( except prophylaxis docetaxel administration ) Estrogens Azoles Macrolides Cyclosporine Rifampin Phenytoin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>